Fact CheckerSign in

NCT04266977Recruiting

Restrictive Use of Dexamethasone in Glioblastoma

Source: ClinicalTrials.gov · Last updated 9 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

The administration of steroids, most commonly dexamethasone (DEX), has established as standard of care during treatment of glioblastoma (GBM) and is widely used during the entire course of the disease including pre- and postoperative management, chemo- and radiotherapy. The primary purpose is to reduce tumor-associated vasogenic edema and to prevent or treat increased intracranial pressure. However, steroids are also linked to a multitude of adverse side effects that may affect survival of GBM patients such as major immunosuppression. The use of steroids during radiotherapy is associated with reduced overall- and progression-free survival and has been identified as an independent poor prognostic factor. Despite these findings, the suspicion of GBM often triggers the administration of DEX in routine clinical practice, regardless of neurological symptoms, tumor size, or extension of cerebral edema. The purpose of this study is to assess whether selected GBM patients can be treated safely with a restrictive DEX regimen from referral to the neurosurgical center until discharge. The primary objective is to determine the failure rate of a restrictive DEX regimen defined as edema or mass effect leading to any of the following: GCS deterioration ≥ 2 points, NIHSS increase ≥ 3 points, increase of midline Shift ≥ 2mm, or any surgical rescue procedure for increasing mass effect.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
50 (estimated)
First submitted
3 Feb 2020
Start date
8 May 2020
Primary completion date
Apr 2027
Lead sponsor
Insel Gruppe AG, University Hospital Bern
Diseases
Glioblastoma
NCT number
NCT04266977

What you commit to

  • Study type: Interventional
  • Planned participants: 50
  • From 8 May 2020 to the primary completion date, Apr 2027
  • 4 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Therapy with steroids for \>1 day before inclusion
  • Need for treatment with steroids due to any other disease
  • Contraindications to the administration of Dexamethasone

Other

  • Infratentorial lesions, brainstem lesions, multifocal lesions
  • Pregnancy or breastfeeding

Who the study is looking for

  • Newly diagnosed supratentorial contrast enhancing lesion suspicious of glioblastoma without major mass effect, amenable to surgical resection
  • Age 18 - 90 years
  • Midline Shift ≤ 3mm
  • GCS ≥ 14
  • NIHSS ≤ 3
  • Provided written informed consent

Age in the registry: 18 years to 90 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (4)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Universitätsspital Basel
Coordinator of this site? Confirm its status
BaselSwitzerlandNot yet recruiting
Department of Neurosurgery
Coordinator of this site? Confirm its status
BernSwitzerlandRecruiting
Kantonsspital St. Gallen
Coordinator of this site? Confirm its status
Sankt GallenSwitzerlandNot yet recruiting
Universitätsspital Zürich
Coordinator of this site? Confirm its status
ZurichSwitzerlandNot yet recruiting

This page is information, not medical advice. Discuss any trial with your doctor.